Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M5,129Revenue (TTM) $M37.2Net Margin (%)-784.0Altman Z-Score13.5
Enterprise Value $M4,936EPS (TTM) $-7.1Operating Margin %-742.0Piotroski F-Score5
P/E(ttm)--Beneish M-Score--Pre-tax Margin (%)-784.0Higher ROA y-yY
Price/Book27.110-y EBITDA Growth Rate %--Quick Ratio5.5Cash flow > EarningsY
Price/Sales1235-y EBITDA Growth Rate %--Current Ratio5.6Lower Leverage y-yY
Price/Free Cash Flow--y-y EBITDA Growth Rate %--ROA % (ttm)-89.2Higher Current Ratio y-yN
Dividend Yield %--PEG--ROE % (ttm)-188.1Less Shares Outstanding y-yN
Payout Ratio %--Shares Outstanding M51.4ROIC % (ttm)--Gross Margin Increase y-yY

Gurus Latest Trades with TSRO

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
TSRORon Baron 2016-06-30 Add$37.21 - $84.05
($44.58)
$ 99.86124%Add 85.00%3,700
TSRORon Baron 2016-03-31 Buy $32.01 - $52.32
($40.2)
$ 99.86148%New holding2,000
TSRODavid Swensen 2015-12-31 Sold Out -0.08%$40.35 - $52.91
($47.98)
$ 99.86108%Sold Out0
TSRODavid Swensen 2015-09-30 Buy 0.08%$38.97 - $65.8
($54.68)
$ 99.8683%New holding6,238
TSROLeon Cooperman 2015-06-30 Sold Out -0.05%$50.84 - $64.65
($57.38)
$ 99.8674%Sold Out0
TSROLeon Cooperman 2015-03-31 Buy 0.05%$36.62 - $61.41
($47.12)
$ 99.86112%New holding50,000
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

TSRO is held by these investors:

Premium Most recent portfolio changes are included for Premium Members only!


TSRO: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Huber Martin H. Jr.SVP & Chief Medical Officer 2016-09-22Sell408$108.12-7.64view
English Edward CV.P.Finance and Administration 2016-09-08Sell7,000$88.5412.79view
Hanke Jeffrey H.Executive VP, R&D and CSO 2016-08-30Sell29,166$86.0416.06view
Hanke Jeffrey H.Executive VP, R&D and CSO 2016-06-30Sell12,500$74.3534.31view
English Edward CVP of Finance & Administration 2016-06-10Sell7,000$40.75145.06view
Weller Harry R10% Owner 2016-03-18Buy1,420,858$35.19183.77view
Viswanathan Ravi10% Owner 2016-03-18Buy1,420,858$35.19183.77view
SANDELL SCOTT D10% Owner 2016-03-18Buy1,420,858$35.19183.77view
MOTT DAVID MDirector, 10% Owner 2016-03-18Buy1,420,858$35.19183.77view
KERINS PATRICK J10% Owner 2016-03-18Buy710,429$35.19183.77view

Quarterly/Annual Reports about TSRO:

News about TSRO:

Articles On GuruFocus.com
Major Second Quarter Purchases for Cohen include Tesaro, Pernix Jul 20 2016 
Steven Cohen Hits Another Home Run in Oncology Jul 07 2016 
David Swensen Bets on Antero Resources Mar 10 2016 
David Swensen's Transactions Show Diversity of Portfolio Nov 19 2015 

More From Other Websites
TESARO, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Regulation FD... Sep 29 2016
TESARO and Zai Lab Announce Collaboration, Development and License Agreement Sep 29 2016
TESARO and Zai Lab Announce Collaboration, Development and License Agreement Sep 29 2016
7:01 am Tesaro and Zai Lab announce collaboration, development, and license agreement to enable the... Sep 29 2016
[video]Takeover Chatter Around Clovis May Be Overdone Sep 23 2016
'Blockbuster Franchises' Spark M&A Fever For Sarepta, Ariad, Biotechs Sep 21 2016
Is Tesaro Another M&A Target? The Charts Say It Is Sep 21 2016
Looking Ahead To The Potentially Game Changing TESARO Inc (TSRO) Data Sep 14 2016
Tesaro Gets Fast Track Designation for Ovarian Cancer Drug Sep 13 2016
TESARO, Inc. – Value Analysis (NASDAQ:TSRO) : September 12, 2016 Sep 12 2016
TESARO Receives FDA Fast Track Designation for Niraparib and Initiates Rolling NDA Submission Sep 12 2016
TESARO Receives FDA Fast Track Designation for Niraparib and Initiates Rolling NDA Submission Sep 12 2016
Gilead Sciences: What is PARP? Sep 09 2016
TESARO, Inc. breached its 50 day moving average in a Bullish Manner : TSRO-US : September 9, 2016 Sep 09 2016
Clovis Oncology Up As FDA Skips Review Panel For New Drug Sep 08 2016
When Gilead Sciences Speaks… Sep 08 2016
Lake Street Says Buy-Rated Tesaro Holds An Attractive Portfolio Of Cancer Therapies Sep 06 2016
TESARO Announces Six Data Presentations at the 2016 European Society for Medical Oncology (ESMO)... Sep 06 2016
Coverage initiated on Tesaro by BofA/Merrill Aug 30 2016

Add Notes, Comments

If you want to ask a question or report a bug, please create a support ticket.
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)